Related Experiment Video
Updated: Apr 25, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Evolution of treatment regimens in multiple myeloma: a social network analysis
Helen Mahony1, Athanasios Tsalatsanis1, Ambuj Kumar1
1Department of Internal Medicine, Division of Evidence-Based Medicine & Health Outcomes Research, University of South Florida, Tampa, Florida, United States of America.
Background:
Randomized controlled trials (RCTs) are considered the gold standard for assessing the efficacy of new treatments compared to standard treatments. However, the reasoning behind treatment selection in RCTs is often unclear. Here, we focus on a cohort of RCTs in multiple myeloma (MM) to understand the patterns of competing treatment selections.
Methods:
We used social network analysis (SNA) to study relationships between treatment regimens in MM RCTs and to examine the topology of RCT treatment networks. All trials considering induction or autologous stem cell transplant among patients with MM were eligible for our analysis. Medline and abstracts from the annual proceedings of the American Society of Hematology and American Society for Clinical Oncology, as well as all references from relevant publications were searched. We extracted data on treatment regimens, year of publication, funding type, and number of patients enrolled. The SNA metrics used are related to node and network level centrality and to node positioning characterization.
Results:
135 RCTs enrolling a total of 36,869 patients were included. The density of the RCT network was low indicating little cohesion among treatments. Network Betweenness was also low signifying that the network does not facilitate exchange of information. The maximum geodesic distance was equal to 4, indicating that all connected treatments could reach each other in four "steps" within the same pathway of development. The distance between many important treatment regimens was greater than 1, indicating that no RCTs have compared these regimens.
Conclusion:
Our findings show that research programs in myeloma, which is a relatively small field, are surprisingly decentralized with a lack of connectivity among various research pathways. As a result there is much crucial research left unexplored. Using SNA to visually and analytically examine treatment networks prior to designing a clinical trial can lead to better designed studies.
Insights
Randomized controlled trials in multiple myeloma are decentralized, with few direct comparisons between key treatments. This lack of connectivity reveals unexplored research, suggesting social network analysis can improve future trial design.
Area of Science:
- Hematology
- Clinical Trials
- Network Science
Background:
- Randomized controlled trials (RCTs) are crucial for evaluating new treatments.
- The rationale for selecting treatments in RCTs is often not well-defined.
- Understanding treatment selection patterns in multiple myeloma (MM) RCTs is important.
Purpose of the Study:
- To analyze treatment selection patterns in multiple myeloma (MM) randomized controlled trials (RCTs).
- To examine the network topology of treatment regimens within MM RCTs using social network analysis (SNA).
Main Methods:
- A comprehensive search of Medline and conference abstracts was conducted for MM RCTs.
- Data extracted included treatment regimens, publication year, funding, and patient enrollment.
- Social network analysis (SNA) metrics were applied to evaluate network structure and centrality.
Main Results:
- 135 RCTs with 36,869 patients were analyzed, revealing a low-density treatment network.
- Low Network Betweenness indicated limited information exchange between treatments.
- A maximum geodesic distance of 4 suggested limited direct comparisons, with many important regimens not yet compared in RCTs.
Conclusions:
- Multiple myeloma research exhibits surprising decentralization and poor connectivity among research pathways.
- Significant unexplored research exists due to the lack of direct treatment comparisons in RCTs.
- Employing SNA before clinical trial design can enhance study planning and research efficiency.
More Related Videos
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Cancer Survival Analysis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
Therapeutic Drug Monitoring: Overview and Classification